|Bid||177.40 x 0|
|Ask||178.20 x 0|
|Day's Range||175.70 - 178.40|
|52 Week Range||117.75 - 195.60|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||274.63|
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 685,000 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 68,500 new shares were subscribed for in cash at DKK 131.40 per share of nominally DKK 10.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first half of 2019 and releases its financial calendar for 2020. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We have made important progress in our strategic objectives during the first half of this year with the initiation of a Phase 3 study for the freeze-dried formulation of MVA-BN and the expansion of our proof of concept Phase 2 study for BN-Brachyury. It is a very exciting time to be at Bavarian Nordic”.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) applauds the U.S. Government’s final passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019 which reauthorizes and improves funding for critical federal biodefense programs and agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Strategic National Stockpile (SNS) collectively with US$ 1.2 billion annually over the next five years, and the Project BioShield Special Reserve Fund (SRF) with US$ 710 million annually over 10 years. Through contracts with BARDA, the Company has to-date supplied 28 million doses of the vaccine for emergency use to the SNS and is currently preparing for re-supply of the vaccine in an improved, freeze-dried formulation.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects. The randomized, double-blind, multicenter trial will evaluate the immunogenicity and safety of three consecutive vaccine lots of the freeze-dried formulation of MVA-BN® smallpox vaccine, similar to the prior completed Phase 3 study for the liquid-frozen MVA-BN formulation.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Data and Safety Monitoring Board (DSMB) confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint. As this meets the initial pre-defined threshold of activity for the first stage of the Phase 2 trial, recruitment will be expanded to enroll another 19 patients, while the first 10 patients continue to be treated and evaluated. The proof-of-concept Phase 2 trial was designed to determine if the combination of BN-Brachyury and radiation therapy, the current standard of care, results in a clinically meaningful objective response rate (ORR), measured as a percentage of patients with a decrease in tumor size within 12 months of radiation therapy.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the share buy-back program, which was announced and initiated on May 22, 2019, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which together constitute the Safe Harbour Regulation. Under the program Bavarian Nordic A/S has bought back 28,849 shares, cf.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 28,849 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy and the general guidelines for incentive remuneration. Bavarian Nordic A/S has appointed Danske Bank A/S Lead Manager of the program.
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first three months of 2019. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “As outlined in our strategy, 2019 and 2020 will be transitional years for Bavarian Nordic with significant investments in R&D and our new fill and finish facility, all with the objective to secure future revenue, growth and profitability. Also, the approval will trigger the award of a Priority Review Voucher which, when sold, will contribute to maintaining a strong financial position.
COPENHAGEN, Denmark – May 14, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2019 first quarter results on Wednesday, May 22, 2019. The management of.
The Board of Directors’ proposal to transfer the Company’s result to next year was also adopted. The General Meeting adopted a resolution to discharge the Board of Directors and the Board of Management from their obligations. The proposal to increase and extend the Board of Directors' authorization to increase the share capital of the Company was adopted.
In 2014 Paul Chaplin was appointed CEO of Bavarian Nordic A/S (CPH:BAVA). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider...
A resolution to discharge the Board of Directors and the Board of Management from their obligations. Proposal to increase and extend the authorisations of the Board of Directors in Article 5a of the Articles of Association, so that the Board of Directors until 30 June 2020 is authorised to increase the share capital of the Company by nominally DKK 32,310,560, corresponding to 10% of the Company's share capital.
COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2018. Below is a summary of business progress, financial performance for the year and financial outlook for 2019 from the report. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: "We made excellent progress on our pipeline assets and delivered on all our plans in 2018.
COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board ...
The BLA was granted a priority review in December 2018, originally targeting a six months review process. The BLA maintains priority review status with the FDA, and thus Bavarian Nordic would still be eligible to receive a Priority Review Voucher when MVA-BN is approved.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of Bavarian Nordic A/S (CPH:BAVA)Read More...